Identification and characterization of a selective peroxisome proliferator-activated receptor β/δ (NR1C2) antagonist

Molecular Endocrinology

Volumn 22, Issue 2, 2008, Pages 523-529

  Shearer, Barry G ^a   Steger, David J ^c   Way, James M ^a   Stanley, Thomas B ^a   Lobe, David C ^a   Grillot, Didier A ^b   Iannone, Marie A ^a   Lazar, Mitchell A ^c   Willson, Timothy M ^a   Billin, Andrew N ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; GSK 0660; GSK 1491; GW 1516; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; DRUG ANTAGONISM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SELECTIVITY; FATTY ACID OXIDATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MOLECULAR STRUCTURE; MUSCLE, SKELETAL; OXIDATION-REDUCTION; PPAR DELTA; PPAR-BETA; SULFONES; THIAZOLES; THIOPHENES;

ANIMALIA;

EID: 38749152401     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0190     Document Type: Article

References (29)

1. Wallace JM, Schwarz M, Coward P, Houze J, Sawyer JK, Kelley KL, Chai A, Rudel LL 2005 Effects of peroxisome proliferator-activated receptor α/δ agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 46:1009-1016
2. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK 2004 Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J Clin Invest 114:1564-1576
3. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J 2003 Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924-15929
4. Oliver Jr WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM 2001 A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311
5. Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson TM, Hassall DG, Ancellin N, Patterson SD, Lobe DC, Johnson TG 2007 Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arterioscler Thromb Vasc Biol 27:359-365
6. Wang D, Mann JR, DuBois RN 2004 WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth. Cell Cycle 3:1512-1515
7. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM 2006 The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cell Signal 18:9-20
8. Lopez-Soriano J, Chiellini C, Maffei M, Grimaldi PA, Argiles JM 2006 Roles of skeletal muscle and peroxisome proliferator-activated receptors in the development and treatment of obesity. Endocr Rev 27:318-329
9. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi PA 2003 Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability. FASEB J 17:2299-2301
10. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM 2004 Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol 2:e294
11. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM 2006 PPARδ regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103:3444-3449
12. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM, Blanchard SG 2002 Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640-6650
13. Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, Voegel JJ, Vignon F, Nicolas JC, Balaguer P 2005 Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands. Anal Biochem 344:8-15
14. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, McKee DD, Galardi CM, Plunket KD, Nolte RT, Parks DJ, Moore JT, Kliewer SA, Willson TM, Stimmel JB 2002 Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα. Nature 415:813-817
15. Nakano R, Kurosaki E, Yoshida S, Yokono M, Shimaya A, Maruyama T, Shibasaki M 2006 Antagonism of peroxisome proliferator-activated receptor γ prevents high-fat diet-induced obesity in vivo. Biochem Pharmacol 72:42-52
16. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W 2002 A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16:2628-2644
17. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington Jr WW, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook Jr RA, Noble SA, Oliver Jr W, Parks DJ, Plunket KD, Szewczyk JR, Willson TM 1998 N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 41:5020-5036
18. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver Jr WR, Sternbach DD 2003 Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)-synthesis and biological activity. Bioorg Med Chem Lett 13:1517-1521
19. Takahashi S, Tanaka T, Kodama T, Sakai J 2006 Peroxisome proliferator-activated receptor δ (PPARδ), a novel target site for drug discovery in metabolic syndrome. Pharmacol Res 53:501-507
20. Hall JM, McDonnell DP 2007 The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages. Mol Endocrinol 21:1756-1768
21. Kallenberger BC, Love JD, Chatterjee VK, Schwabe JW 2003 A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nat Struct Biol 10:136-140
22. Tamrazi A, Carlson KE, Katzenellenbogen JA 2003 Molecular sensors of estrogen receptor conformations and dynamics. Mol Endocrinol 17:2593-2602
23. Westin S, Rosenfeld MG, Glass CK 2000 Nuclear receptor coactivators. Adv Pharmacol 47:89-112
24. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468
25. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852
26. Shi Y, Hon M, Evans RM 2002 The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 99:2613-2618
27. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P 2001 A PPAR γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171
28. Alenghat T, Yu J, Lazar MA 2006 The N-CoR complex enables chromatin remodeler SNF2H to enhance repression by thyroid hormone receptor. EMBO J 25:3966-3974
29. Iannone MA, Simmons CA, Kadwell SH, Svoboda DL, Vanderwall DE, Deng SJ, Consler TG, Shearin J, Gray JG, Pearce KH 2004 Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Mol Endocrinol 18:1064-1081